Financial Review: Quipt Home Medical (NASDAQ:QIPT) & BioRestorative Therapies (NASDAQ:BRTX)

BioRestorative Therapies (NASDAQ:BRTX) and Quipt Home Medical (NASDAQ:QIPT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Institutional and Insider Ownership

69.4% of BioRestorative Therapies shares are owned by institutional investors. Comparatively, 42.9% of Quipt Home Medical shares are owned by institutional investors. 25.5% of BioRestorative Therapies shares are owned by company insiders. Comparatively, 13.4% of Quipt Home Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares BioRestorative Therapies and Quipt Home Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioRestorative Therapies	$150,000.00	105.65	-$14.41 million	($1.53)	-1.50
Quipt Home Medical	$245.91 million	0.52	-$6.76 million	($0.15)	-19.80

Quipt Home Medical has higher revenue and earnings than BioRestorative Therapies. Quipt Home Medical is trading at a lower price-to-earnings ratio than BioRestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioRestorative Therapies has a beta of 62.62, suggesting that its stock price is 6,162% more volatile than the S&P 500. Comparatively, Quipt Home Medical has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for BioRestorative Therapies and Quipt Home Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioRestorative Therapies	0	0	1	0	3.00
Quipt Home Medical	1	0	3	2	3.00

BioRestorative Therapies presently has a consensus target price of $18.00, suggesting a potential upside of 686.03%. Quipt Home Medical has a consensus target price of $6.25, suggesting a potential upside of 110.44%. Given BioRestorative Therapies’ higher possible upside, research analysts clearly believe BioRestorative Therapies is more favorable than Quipt Home Medical.

Profitability

This table compares BioRestorative Therapies and Quipt Home Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioRestorative Therapies	-2,697.08%	-98.49%	-75.23%
Quipt Home Medical	-2.66%	-6.18%	-2.73%

Summary

Quipt Home Medical beats BioRestorative Therapies on 8 of the 14 factors compared between the two stocks.

About BioRestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

About Quipt Home Medical

Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.